Stifel Maintains Buy on Medline, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 67.5%

Neg 67.5% Neu 0% Pos 0%

Stifel analyst Rick Wise maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $50 to $45.

Comments

No comments yet. Be the first!